Inbakicept
Inbakicept is a protein pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| anktiva | Biologic Licensing Application | 2024-05-09 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
43 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 5 | 10 | 1 | — | — | 11 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 4 | 2 | — | — | 5 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 1 | 4 | 1 | — | — | 4 |
| Urinary bladder neoplasms | D001749 | — | C67 | 1 | 2 | 1 | — | 1 | 3 |
| Non-muscle invasive bladder neoplasms | D000093284 | — | — | 1 | 2 | 1 | — | 1 | 3 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 6 | 2 | — | — | — | 7 |
| Squamous cell carcinoma | D002294 | — | — | 3 | 5 | — | — | — | 6 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 2 | 5 | — | — | — | 6 |
| Colorectal neoplasms | D015179 | — | — | 2 | 5 | — | — | — | 5 |
| Hiv | D006678 | — | — | 4 | 1 | — | — | — | 4 |
| Merkel cell carcinoma | D015266 | EFO_1001471 | C4A | — | 3 | — | — | — | 3 |
| Head and neck neoplasms | D006258 | — | — | 1 | 3 | — | — | — | 3 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 3 | 1 | — | — | — | 3 |
| Neoplasms | D009369 | — | C80 | 3 | 2 | — | — | — | 3 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | 2 | — | — | — | 2 |
Show 32 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | — | — | 1 |
| Plasma cell neoplasms | D054219 | — | — | 1 | — | — | — | — | 1 |
| Covid-19 | D000086382 | — | — | 1 | — | — | — | — | 1 |
| Immunologic deficiency syndromes | D007153 | HP_0002721 | D84.9 | 1 | — | — | — | — | 1 |
| Hodgkin disease | D006689 | — | C81 | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics | D010599 | — | — | — | — | — | — | 1 | 1 |
| Invasive hydatidiform mole | D002820 | — | D39.2 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Inbakicept |
| INN | inbakicept |
| Description | Inbakicept is a protein pharmaceutical. It is currently being investigated in clinical studies. |
| Classification | Protein |
| Drug class | receptor molecules or membrane ligands, natural, modified or modified |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4594318 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | QN4LI58PJ5 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use